Reporter brief
Rapamycin injections tested for safety and efficacy in treatment-naive age-related macular degeneration: Phase 1/2 RCT
What happened
A Phase 1/2 randomized controlled trial evaluated sirolimus (rapamycin) administered via different injection routes in patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration. The study assessed safety and efficacy outcomes, though specific effect sizes and patient numbers were not reported in the provided abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Design
- Rct
- Sample
- —
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.